These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10800475)

  • 1. Antimetabolites.
    Grem JL; Takimoto CH; Multani P; Chu E; Ryan D; Chabner BA; Allegra CJ; Johnston PG
    Cancer Chemother Biol Response Modif; 1999; 18():1-38. PubMed ID: 10800475
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
    Schirmer M; Stegmann AP; Geisen F; Konwalinka G
    Exp Hematol; 1998 Dec; 26(13):1223-8. PubMed ID: 9845378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeking the nucleoside transporter.
    Wiley JS
    Nat Med; 1997 Jan; 3(1):25-6. PubMed ID: 8986733
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
    Hubeek I; Peters GJ; Broekhuizen AJ; Kaspers GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1513-6. PubMed ID: 15571288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Fidias P; Grossbard ML; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1997; 17():1-39. PubMed ID: 9551206
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
    Clarke ML; Mackey JR; Baldwin SA; Young JD; Cass CE
    Cancer Treat Res; 2002; 112():27-47. PubMed ID: 12481710
    [No Abstract]   [Full Text] [Related]  

  • 7. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
    Csoka K; Liliemark J; Larsson R; Nygren P
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):47-53. PubMed ID: 7481845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53.
    Cory AH; Cory JG
    Adv Enzyme Regul; 2004; 44():11-25. PubMed ID: 15581479
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimetabolites.
    Chu E; Johnston PG; Grem JL; Takimoto CH; Van Groeningen C; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1994; 15():1-31. PubMed ID: 7779582
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimetabolites.
    Chu E; Grem JL; Johnston PG; Politi PM; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1992; 13():1-30. PubMed ID: 1389906
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimetabolites.
    Chu E; Johnston PG; Takimoto CH; Politi PM; Grem JL; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1993; 14():1-25. PubMed ID: 8312100
    [No Abstract]   [Full Text] [Related]  

  • 13. Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
    Liu QH; Zhang J; Zhao CY; Yu DH; Bu HJ; Chen Y; Ni CY; Zhu MH
    Cancer Lett; 2012 Jan; 314(1):119-25. PubMed ID: 21983131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia.
    Schirmer M; Geisen F; Tiefenthaler M; Konwalinka G
    Leuk Res; 1999 Dec; 23(12):1121-6. PubMed ID: 10613357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetabolites.
    Allegra CJ; Baram J; Chabner BA; Yeh GC; Aiba K; Curt GA
    Cancer Chemother Biol Response Modif; 1987; 9():1-22. PubMed ID: 2484324
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.
    Peters GJ; Voorn DA; Kuiper CM; van der Wilt CL; Noordhuis P; Smid K; Myhren F; Sandvold M; Hendriks HR
    Nucleosides Nucleotides; 1999; 18(4-5):877-8. PubMed ID: 10432699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3 upregulation drives gemcitabine resistance.
    Maciejowski J; Mohamed T
    Nat Cancer; 2024 Jun; 5(6):818-820. PubMed ID: 38778178
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines.
    Bergman AM; Kuiper CM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1523-6. PubMed ID: 15571290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor resistance to antimetabolites.
    Kinsella AR; Smith D
    Gen Pharmacol; 1998 May; 30(5):623-6. PubMed ID: 9559310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.